Octreotide Acetate CAS 83150-76-9 Peptide Purity (HPLC) ≥98.0% API Ogo dị elu

Octreotide Acetate (Sandostatin) bụ ihe analọgụ sịntetik peptide nke homonụ somatostatin, ọ bụ analọgụ somatostatin na-eme ogologo oge egosiputara maka njikwa akara na etuto acromegaly na gastroenteropancreatic.Enwere ike iji ya eme ihe ndị ọzọ a na-enyocha gụnyere ọrịa shuga, psoriasis na ọrịa Alzheimer.Octreotide Acetate (Sandostatin) bụ ihe analọgụ peptide synthetic nke homonụ somatostatin.Ihe omume ya gụnyere igbochi pituitary secretion nke homonụ na-eto eto na mgbochi nke mmepụta insulin na glucagon cell islet pancreatic.N'adịghị ka somatostatin, nke nwere ọkara ndụ plasma nke nkeji ole na ole, Octreotide nwere mkpochapụ plasma ọkara ndụ nke 1 ruo 2 awa.Mwepu nke ọgwụ bụ isi gbasara akụrụ.Octreotide na-ebelata motility eriri afọ ma na-egbochi mkpụkọ nke eriri afọ.

Ọgwụ Peptide Novartis Sandostatin (Octreotide Acetate), bụ ihe na-emepụta somatostatin octapeptide eke synthetic, ọ na-ejigide mmetụta ọgwụ dị ka nke somatostatin, mmetụta ya na-adịte aka.Ihe ngosi maka Octreotide Acetate gụnyere acromegaly;Mbelata nke mgbaàmà na ihe ịrịba ama metụtara ọrụ gastroenteropancreatic endocrine neoplasia;Na ịdị irè na Tumor Carcinoid na-egosi ọrịa carcinoid, etuto VIP, na etuto glucagon.Na mgbakwunye, Octreotide Acetate maka gastrinomas / Zollinger-Ellison syndrome (na-ejikarị ya na proton pump inhibitors ma ọ bụ H2 receptor blockers), Insulinomas (mgbochi hypoglycemia tupu oge eruo na ịnọgide na-enwe shuga ọbara nkịtị), ọnụ ọgụgụ dị irè nke hormone uto na-ewepụta etuto ahụ bụ. ihe dịka 50%.

Octreotide Acetate bụ ọgwụ mkpuchi ahụike mba nke Klas B, nke bụ ihe sitere na octapeptide eke sitere na somatostatin, ma e jiri ya tụnyere somatostatin anụ ahụ, ọkara ndụ somatostatin doro anya na ọ dị ogologo ma nwee otu mmetụta ọgwụ ahụ, gụnyere igbochi ọrụ homonụ uto, mgbochi. nke gastric acid, pancreatic enzyme, glucagon na insulin secretion, na mbelata nke ọbara visceral, mbelata eriri afọ motility.Tụnyere nwa amaala somatostatin, octreotide nwere ogologo ndụ ọkara, ọ na-ahọrọ maka igbochi mmepụta homonụ uto karịa igbochi insulin secretion, ọ naghị ebute hypersecretion nke homonụ.1, nchịkwa ịwa ahụ ma ọ bụ ọgwụgwọ radieshon enweghị ike ịchịkwa ọrịa ahụ nke ọma na ndị ọrịa nwere akara acromegaly ma belata ihe na-eto eto nke onye ọrịa (GH) insulin-like growth factor -1 (1GF-1) ọkwa plasma.A pụkwara iji Sandostatin na-agwọ ndị ọrịa nwere acromegaly ndị na-enweghị ike ma ọ bụ na-achọghị ịwa ahụ, ma ọ bụ na-agwọ ndị ọrịa nwere acromegaly ndị na-enwebeghị ọgwụgwọ radieshon.2. Mbelata nke mgbaàmà metụtara arụ ọrụ gastroenteropancreatic (GEP) endocrine etuto dị ka carcinoid etuto na carcinoid ọrịa ngosipụta.Sandostatin abụghị ọgwụ mgbochi ọrịa kansa na ọ naghị agwọ ndị ọrịa a.3, Mgbochi nsogbu mgbe ịwa ahụ pancreatic.4, Ndị na-arịa ọrịa imeju na-arịa ọrịa afọ-esophageal variceal ọbara ọgbụgba kpatara site na ọgwụgwọ mberede, hemostasis na mgbochi nke rebleeding, Sandostatin kwesịrị ijikọta ya na endoscopic sclerotherapy na ọgwụgwọ ndị ọzọ pụrụ iche.